| Name | Title | Contact Details |
|---|
Porter is a Bishop, CA-based company in the Business Services sector.
Marsh Furniture Company is a family-owned cabinetry manufacturer based in High Point, North Carolina, established in 1906. The company specializes in kitchen and bath cabinetry, offering a product line known as Marsh Cabinets. These cabinets feature traditional face frame construction and are available in various wood species, including Oak, Birch, Maple, and Cherry. Marsh is recognized for its durable and stylish storage solutions, catering to both residential remodels and large-scale developments. Operating from a 700,000-square-foot facility, Marsh combines traditional craftsmanship with modern innovation. The company emphasizes quality and service while maintaining strong relationships with independent kitchen and bath dealers across the eastern United States. Marsh Furniture Company is committed to the well-being of its employees and the local community, reflecting over a century of dedication to integrity and craftsmanship.
BKD CPAs & Advisors is a top-tier CPA and advisory firm dedicated to helping people and businesses realize their goals. Our approximately 2,900 dedicated professionals offer solutions to clients in all 50 states and internationally. Our expertise goes well beyond the standard accounting services to include risk management, technology, wealth management and forensic and valuation services. Our clients represent a wide range of industries, and were even part of an alliance of firms that gives us a global reach.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.